Meta-analysis of gender differences in efficacy outcomes for HIV-positive subjects in randomized controlled clinical trials of antiretroviral therapy (2000-2008)

AIDS Patient Care and STDs

Volumn 26, Issue 8, 2012, Pages 444-453

  Soon, Guoxing ^a   Min, Min ^a   Struble, Kimberly A ^a   Chan Tack, Kirk M ^a   Hammerstrom, Thomas ^a   Qi, Karen ^a   Zhou, Susan ^a   Bhore, Rafia ^b   Murray, Jeffrey S ^a   Birnkrant, Debra B ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR PLUS RITONAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; FOSAMPRENAVIR; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; ARTICLE; CONTROLLED STUDY; DATA BASE; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEX DIFFERENCE; SYSTEMATIC REVIEW (TOPIC); TREATMENT OUTCOME;

ANTI-HIV AGENTS; FEMALE; HEALTH STATUS DISPARITIES; HIV SEROPOSITIVITY; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEX DISTRIBUTION; SEX FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84864719749     PISSN: 10872914     EISSN: 15577449     Source Type: Journal    
DOI: 10.1089/apc.2011.0278     Document Type: Article

References (53)

1. Panel on Antiretroviral Guidelines for Adult and Adolescents. Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents-January 10, 2011;1-166. http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf (Last accessed March 9, 2012).
2. EMEA/CHMP Guideline on the Clinical Development of Medicinal Products for the Treatment of HIV Infection. www.ema.europa.eu/docs/en-GB/document-library/ Scientific-guideline/2009/09/WC500003399.pdf (Last accessed March 9, 2012).
3. Gazzard B, Bernard AJ, Boffito M, et al. British HIV Association (BHIVA) guidelines for the treatment of HIV-positive adults with antiretroviral therapy. 2008 www.bhiva.org (Last accessed March 9, 2012).
4. Forum for Collaborative HIV Research-Racial and Ethnic Minority Issues in the Management of HIV Care, Prevention and Research. www.hivforum.org/storage/ hivforum/documents/FinalREINov06%20report.pdf (Last accessed March 9, 2012).
5. Feinberg J, Japour AJ. Scientific and ethical considerations in trial design for investigational agents for the treatment of human immunodeficiency virus infection. Clin Infect Dis 2003;36:201-206.
6. King WD, Defreitas D, Smith K, et al., on behalf of Underrepresented Populations Committee of the Adult AIDS Clinical Trials Group (AACTG). Attitudes and perceptions of AIDS clinical trials group site coordinators on HIV clinical trial recruitment and retention: A descriptive trial. AIDS Patient Care STDs 2007;21:551-563.
7. Chan-Tack KM, Struble KA, Morgensztejn N, et al. HIV clinical trial design for antiretroviral development: Moving forward. AIDS 2008;22:2419-2427.
8. The Well Project: Women's Research Initiative on HIV/AIDS. www.thewellproject.org (Last accessed March 9, 2012).
9. Golub ET, Benning L, Sharma A, et al. Patterns, predictors, and consequences of initial regimen type among HIV-positive women receiving highly active antiretroviral therapy. Clin Infect Dis 2008;46:305-312.
10. Tedaldi EM, Absalon J, Thomas AJ, et al. Ethnicity, race, and sex. Differences in serious adverse events among participants in an antiretroviral initiation trial: Results of CPCRA 058 (FIRST Trial). J Acquir Immune Defic Syndr 2008;47:441-448.
11. Floridia M, Giuliano M, Palmisano L, Vella S. Sex differences in the treatment of HIV infection. Pharmacol Res 2008;58: 173-182.
12. French AL, Gawel SH, Hershow R, et al. Trends in mortality and causes of death among women with HIV in the United States: A 10-year trial. J Acquir Immune Defic Syndr 2009; 51:399-406.
13. Kunches L, Reinhalter NE, Marquis A, et al. Tolerability of enteric-coated didanosine capsules compared with didanosine tablets in adults with HIV infection. J Acquir Immune Defic Syndr 2001;28:150-153.
14. Eron JJ, Feinberg J, Kessler HA, et al. Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naïve HIVpositive patients. J Infect Dis 2004;189:51-60.
15. Haas DW, Zala C, Schrader S, et al. Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: A randomized comparative pilot trial. AIDS 2003;17:1339-1349.
16. UNAIDS 2008 Epidemiology Slides. www.unaids.org/en/KnowledgeCentre/ HIVData/Epidemiology/epidemiology SlidesAuto.asp (Last accessed March 9, 2012).
17. Ortego C, Huedo-Medina TB, Llorca J, et al. Adherence to highly active antiretroviral therapy (HAART): A metaanalysis. AIDS Behav (in press).
18. Napravnik S, Poole C, Thomas JC, et al. Gender difference in HIV RNA levels: A meta-analysis of published studies. J Acquir Immune Defic Syndr 2002;31:11-19
19. GlaxoSmithKline. Abacavir (Ziagen) product information, 2010.
20. GlaxoSmithKline. Abacavir/Lamivudine/Zidovudine (Trizivir) product information, 2011.
21. GlaxoSmithKline. Abacavir/Lamivudine (Epzicom) product information, 2011.
22. Bristol Myers Squibb. Didanosine (Videx) product information, 2006.
23. Bristol Myers Squibb. Didanosine (Videx) product information, 2010.
24. Gilead Sciences, LLC. Emtricitabine (Emtriva) product information, 2010.
25. Gilead Sciences, LLC. Tenofovir/Emtricitabine (Truvada) product information, 2010.
26. Gilead Sciences, LLC. Tenofovir (Viread) product information, 2010.
27. Bristol-Myers Squibb & Gilead Sciences, LLC. Efavirenz/emtricitabine/ tenofovir disoproxil fumarate (Atripla) product information, 2010.
28. GlaxoSmithKline. Lamivudine (Epivir) product information, 2008.
29. GlaxoSmithKline. Zidovudine/Lamivudine (Combivir) product information, 2010.
30. GlaxoSmithKline. Zidovudine (Retrovir) product information, 2010.
31. Bristol Myers Squibb. Stavudine (Zerit) product information, 2005.
32. Bristol Myers Squibb. Efavirenz (Sustiva) product information, 2010.
33. Tibotec, Inc. Etravirine (Intelence) product information, 2010.
34. Boehringer Ingelheim Pharmaceuticals Inc. Nevirapine (Viramune) product information, 2011.
35. Bristol Myers Squibb. Atazanavir (Reyataz) product information, 2011.
36. Tibotec, Inc. Darunavir (Prezista) product information, 2006.
37. GlaxoSmithKline. Fosamprenavir (Lexiva) product information, 2010.
38. Merck Inc. Indinavir (Crixivan) product information, 2010.
39. Abbott Laboratories Inc. Lopinavir/ritonavir (Kaletra) product information, 2011.
40. Agouron Pharmaceuticals, Inc. Nelfinavir (Viracept) product information, 2011.
41. Genetech USA Inc. Saquinavir (Invirase) product information, 2010.
42. Boehringer Ingelheim Pharmaceuticals Inc. Tipranavir (Aptivus) product information, 2011.
43. Merck Inc. Ralegravir (Isentress) product information, 2011.
44. Roche Laboratories Inc. Enfuvirtide (Fuzeon) product information, 2009.
45. Pfizer Inc. Maraviroc (Selzentry) product information, 2010.
46. Tibotec, Inc. Darunavir (Prezista) product information, 2008. www.accessdata.fda.gov/drugsatfda-docs/label/2008/021976s003s004lbl.pdf (Last accessed March 9, 2012).
47. Clinical Data Interchange Standards Consortium (CDISC). Available at: www.cdisc.org/standards (Last accessed March 9, 2012).
48. Whitehead A. Meta-analysis of Controlled Clinical Trials. John Wiley & Sons, Ltd., 2002.
49. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-188.
50. Simmonds M, Higgins JPT, Stewart LA, Tierney JF, Clarke MJ, Thompson SG. Meta-analysis of individual patient data from randomized trials: A review of methods used in practice. Clin Trials 2005;2:209-217.
51. Berlin J, Laird N, Sacks H, et al. Comparison of statistical methods for combining event rates from clinical trials. Stat Med 1989;8:141-151.
52. Higgins JPT, Thompson SG. Quantifiying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-1558.
53. Higgins JPT, Thompson SG, Deeks JJ. Measuring inconsistency in meta-analyses. Br Med J 2003;327:557-560.